Oncology (all articles)
Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline.
31 Oct, 2022 | 13:50h | UTC
Cohort Study | Risk factors of pancreatic cancer in patients with Type 2 DM.
31 Oct, 2022 | 13:47h | UTC
Study | No benefit from frailty screening over a geriatric-assessment-for-all approach in older patients with cancer.
31 Oct, 2022 | 13:40h | UTC
Nonsurgical options for risk reduction of contralateral breast cancer in BRCA mutation carriers with early breast cancer.
31 Oct, 2022 | 13:41h | UTCNonsurgical Options for Risk Reduction of Contralateral Breast Cancer in BRCA Mutation Carriers With Early-Stage Breast Cancer – Journal of Clinical Oncology (free for a limited period)
Post-trial follow-up | Pembrolizumab vs. chemotherapy as first-line therapy in PD-L1-expressing non–small-cell lung cancer.
31 Oct, 2022 | 13:39h | UTC
Case Report | Acquired Hemophilia A secondary to an immune checkpoint inhibitor.
31 Oct, 2022 | 13:34h | UTCCommentary: Report Details Rare Case of Acquired Hemophilia A Secondary to Immune Checkpoint Inhibition
Cohort Study | Diverticular disease linked to increased risk of cancer outside the GI tract.
31 Oct, 2022 | 13:33h | UTCCancer risk in patients with diverticular disease: a nationwide cohort study – JNCI: Journal of the National Cancer Institute (link to abstract – $ for full-text)
News Release: Diverticular disease associated with cancer outside gastrointestinal tract – Karolinska Institutet
2022 ETA Guidelines for the management of pediatric thyroid nodules and differentiated thyroid carcinoma.
27 Oct, 2022 | 12:33h | UTCCommentary: New EU Guidelines: Individualize Care for Thyroid Cancer in Kids – Medscape (free registration required)
[News Release] RCT | Shortened course of radiation therapy safe and effective for men with high-risk prostate cancer.
27 Oct, 2022 | 12:32h | UTCNews Release: Shortened course of radiation therapy safe and effective for men with high-risk prostate cancer – ASTRO Annual Meeting
RCT | Continuous enzalutamide after progression of metastatic castration-resistant prostate cancer treated with docetaxel.
27 Oct, 2022 | 12:23h | UTCContinuous enzalutamide after progression of metastatic castration-resistant prostate cancer treated with docetaxel (PRESIDE): an international, randomised, phase 3b study – The Lancet Oncology (link to abstract – $ for full-text)
Expert Consensus | Imaging standardization in metastatic colorectal cancer.
26 Oct, 2022 | 14:36h | UTC
The bleeding cervical cancer patient: systematic approach and management.
26 Oct, 2022 | 14:30h | UTCThe Bleeding Cervical Cancer Patient: Systematic Approach and Management – emDocs
Single-arm P2 study | Toxic effects of stereotactic ablative radiotherapy for up to 5 oligometastases in patients with cancer.
26 Oct, 2022 | 14:28h | UTCTreatment With Stereotactic Ablative Radiotherapy for Up to 5 Oligometastases in Patients With Cancer: Primary Toxic Effect Results of the Nonrandomized Phase 2 SABR-5 Clinical Trial – JAMA Oncology (link to abstract – $ for full-text)
Commentary on Twitter
Population-based phase 2 non-randomized trial of 381 pts w/oligometastatic or oligoprogressive disease & treated w/stereotactic ablative body radiotherapy (SABR) found rates of grade 2, 3,4, & 5 toxicities of 14.2%, 4.2%, 0%, & 0.3%, respectively. https://t.co/dDpdOEvNzk #RadOnc
— JAMA Oncology (@JAMAOnc) September 29, 2022
Guideline | Reporting of surgically removed lymph nodes for breast tumors.
25 Oct, 2022 | 13:20h | UTC
Systematic Review | Mu‐opioid antagonists for opioid‐induced bowel dysfunction in palliative care and people with cancer.
25 Oct, 2022 | 13:13h | UTC
Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
24 Oct, 2022 | 14:12h | UTC
RCT | Effect of peritoneal fixation on lymphocele formation in robot-assisted radical prostatectomy with pelvic lymphadenectomy.
24 Oct, 2022 | 14:05h | UTCEffect of Peritoneal Fixation (PerFix) on Lymphocele Formation in Robot-assisted Radical Prostatectomy with Pelvic Lymphadenectomy: Results of a Randomized Prospective Trial – European Urology (link to abstract – $ for full-text)
Commentary on Twitter
Articles in Press: Effect of Peritoneal Fixation (PerFix) on Lymphocele Formation in Robot-assisted Radical Prostatectomy with Pelvic Lymphadenectomy: Results of a Randomized Prospective Trial https://t.co/QdWtFGJcnm @VladaStudent @SeifriedovaZ @studentova #medtwitter pic.twitter.com/2YvaxxVcVR
— European Urology (@EUplatinum) October 15, 2022
Phase 2 RCT | Nivolumab with or without Ipilimumab combined with stereotactic body radiotherapy for metastatic pancreatic cancer.
24 Oct, 2022 | 14:01h | UTCRandomized Phase II Study of Nivolumab With or Without Ipilimumab Combined With Stereotactic Body Radiotherapy for Refractory Metastatic Pancreatic Cancer (CheckPAC) – Journal of Clinical Oncology (link to abstract – $ for full-text)
Commentary: SBRT Plus Nivolumab/Ipilimumab Yields Meaningful Activity in Metastatic Pancreatic Cancer – Cancer Network
Commentary on Twitter
Phase II CheckPAC Trial in refractory #PancreaticCancer
✅ 37.2% of pts achieved clinical benefit after stereotactic #RadiationTherapy in combination w/ nivolumab and ipilimumab
⛔ PD-L1 score was not associated with benefitRead more: https://t.co/rxDnYvIUMl #JCO #PancSM pic.twitter.com/u7FfQEwN7a
— Journal of Clinical Oncology (@JCO_ASCO) May 9, 2022
Cohort Study | Systemic or vaginal hormone therapy after early breast cancer.
24 Oct, 2022 | 14:00h | UTCNews Release: Hormone replacement therapy doesn’t lead to breast cancer reoccurrence – Oxford University Press
Commentaries:
Hormone Replacement Therapy Won’t Raise Recurrence Rate for Breast Cancer Survivors – HealthDay
ASCO Guideline | Treatment of metastatic colorectal cancer.
20 Oct, 2022 | 12:32h | UTCTreatment of Metastatic Colorectal Cancer: ASCO Guideline – Journal of Clinical Oncology
Commentary: ASCO Guideline Highlights Newest Breakthroughs in the Treatment of Metastatic CRC – ASCO Daily News
Commentary on Twitter
‼️ @ASCO Guideline just published: Treatment of Metastatic Colorectal Cancer
Read in #JCO ➡️ https://t.co/CqWdEoSIjd #crcsm #mCRC pic.twitter.com/3N25Fl02v6
— Journal of Clinical Oncology (@JCO_ASCO) October 17, 2022
Cohort Study | Use of straighteners and other hair products and incident uterine cancer.
20 Oct, 2022 | 12:28h | UTCNews Release: Hair straightening chemicals associated with higher uterine cancer risk – NIH News Releases
Commentaries:
Hair-straightening chemical products linked to increased uterine cancer risk in new study – CNN
Hair straightening chemicals may increase women’s risk of uterine cancer, study finds – NPR
Cohort Study | Genetic sequencing of pancreatic cyst fluid reveals diverse genomic alterations that may guide clinical management.
20 Oct, 2022 | 12:24h | UTCNews Release: Genetic test for pancreatic cancer outperforms current guidelines – University of Pittsburgh
Commentary from the author on Twitter (thread – click for more)
A tweetorial on our study (https://t.co/OCqCRJEMdx). But, first a case: Young female w/ a 1.9 cm incidental pancreatic cyst. No concerning features, but KRAS, TP53 and SMAD4 mutations on molecular testing. Surgical resection: #IPMN w/ a small #PancreaticCancer. #Pathology #GIPath pic.twitter.com/hMJQ4OAUld
— Aatur Singhi, MD PhD (@PancPathologist) October 10, 2022
RCT | Lurbinectedin plus Doxorubicin are no better than physician’s choice of chemotherapy in relapsed small-cell lung cancer.
20 Oct, 2022 | 12:19h | UTCCombination lurbinectedin and doxorubicin versus physician’s choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial – The Lancet Respiratory Medicine (link to abstract – $ for full-text)
Commentary on Twitter
NEW—Lurbinectedin + doxorubicin did not improve overall survival vs control in relapsed SCLC., but did show a favourable haematological safety profile
ATLANTIS trial from Prof Luis Paz-Ares & colleagues https://t.co/oF57GJx7u1 pic.twitter.com/8aoqTqXUl7
— The Lancet Respiratory Medicine (@LancetRespirMed) October 17, 2022
NCCN Guideline | Rectal cancer.
19 Oct, 2022 | 14:25h | UTC
Consensus Recommendations | Radiation therapy in oligometastatic prostate cancer.
19 Oct, 2022 | 14:24h | UTCRelated: AUA/ASTRO Guideline: Clinically localized prostate cancer.